At a glance
Effects
- Lean body composition: Promotes protein synthesis and lipolysis, supporting increases in lean mass and reductions in adipose tissue [5].
- Recovery & tissue repair: Supports collagen synthesis and connective-tissue repair; clinically used to counter wasting and cachexia [6].
- Metabolic regulation: IGF-1 signalling influences glucose homeostasis, carbohydrate and lipid metabolism [3].
- Bone density: Stimulates chondrocyte differentiation and proliferation at epiphyseal growth plates; supports bone mineralisation in adults [5].
- Wellbeing / energy: Adults with GHD receiving replacement therapy often report improved quality of life and energy levels, though effects vary considerably [6].
Recombinant peptide hormone (rhGH)
~2.5–3 hours (subcutaneous)
Subcutaneous injection (primary); IM used occasionally
Schedule III controlled substance (US); prescription-only globally
Up to ~24 hours (serum); isoform tests used in sports doping up to ~48 h
About Somatropin - 191 Amino Acid
Every point here is drawn from public medical and harm-reduction sources. A bracketed number after a claim — like [1]— is a reference: tap it to open the exact source it's based on (numbered list at the bottom). It is not a rating or score. Educational information, not medical advice.
Product specifics
- Est. delivery
- 3–7 business days · EU tracked
Product details as stated by the vendor (claims, not independently verified). Delivery is our standard EU estimate.
What it is
Somatropin (191 AA) is a recombinant human growth hormone (rhGH) — a 191-amino-acid single-chain polypeptide that is bioidentical to the dominant isoform produced by the anterior pituitary gland [1][2]. It is a prescription peptide hormone used clinically to treat growth hormone deficiency (GHD) in adults and children, HIV-associated wasting, and several other growth-related disorders [3].
How it works
Somatropin binds to growth hormone receptors (GHR) on cell membranes — primarily in the liver — activating JAK2/STAT intracellular signalling pathways [4]. This triggers production of insulin-like growth factor-1 (IGF-1), which mediates most of the anabolic downstream effects: stimulation of protein synthesis, lipolysis, chondrocyte proliferation, and carbohydrate metabolism [3][5]. In short: exogenous GH signals the liver to produce IGF-1, which then drives muscle-sparing, fat-mobilising, and tissue-building actions throughout the body [5].
Risks & side effects
Most important: Supraphysiologic doses carry a meaningful risk of promoting insulin resistance and glucose dysregulation — including new-onset type 2 diabetes — because somatropin directly opposes insulin action [7]. There is also a potential signal for increased cancer risk (particularly brain and skin cancers) and tumour recurrence in those with a history of malignancy, meaning active cancer is an absolute contraindication [8].
Common
- Injection-site reactions: pain, redness, swelling, or localised lipodystrophy with repeated use [9]
- Fluid retention: peripheral oedema, joint pain (arthralgia), and myalgia — often transient and dose-related [10]
- Carpal tunnel syndrome / peripheral paraesthesia due to fluid retention pressure [10]
- Elevated fasting blood glucose / reduced insulin sensitivity [7]
- Headache
Serious
- Intracranial hypertension (raised pressure inside the skull): severe headaches, vision changes, papilloedema — requires prompt evaluation [11]
- New-onset or worsening diabetes mellitus; monitor fasting glucose and HbA1c [7]
- Hypothyroidism: somatropin may unmask or worsen thyroid insufficiency; monitor thyroid function [9]
- Adrenal insufficiency (hypoadrenalism): GH therapy can reveal undiagnosed central adrenal deficit [9]
- Pancreatitis (rare but reported): sudden severe abdominal pain requires immediate evaluation [9]
- Scoliosis progression in rapidly growing paediatric patients
Rare
- Anaphylaxis / severe systemic hypersensitivity reaction — seek emergency care immediately [10]
- Increased risk of second neoplasms (intracranial tumours, meningiomas) reported in long-term use in cancer survivors [10]
- Leukemia has been reported in a small number of patients, causal relationship uncertain [8]
- Fatal outcomes in severely obese patients with Prader-Willi syndrome (respiratory failure) [11]
- Anti-GH antibody formation potentially reducing efficacy [12]
Safety & harm reduction
- Active malignancy (cancer): somatropin is absolutely contraindicated [7][11]
- Acute critical illness after open-heart or abdominal surgery, multiple trauma, or acute respiratory failure [7]
- Severely obese patients with Prader-Willi syndrome due to risk of fatal respiratory failure [11]
- Active proliferative or severe non-proliferative diabetic retinopathy [7]
- Closed epiphyses when used for growth promotion (paediatric indication)
- Serum IGF-1: titrate to mid-normal age- and sex-adjusted range; check every 1–2 months during initiation, then every 6 months [13]
- Fasting blood glucose and/or HbA1c: baseline and periodically — dose increases insulin resistance [7]
- Thyroid function (T3, T4, free T4): hypothyroidism may be unmasked; check at baseline and regularly [13]
- Lipid panel: every 6 months once stable [13]
- Fundoscopy if headache or visual changes arise (intracranial hypertension) [11]
- Oral oestrogens: reduce IGF-1 response — women on oral oestrogens may require higher doses [7]
- Glucocorticoids (supraphysiologic doses): attenuate growth-promoting effects [7]
- Insulin / oral antidiabetics: somatropin reduces insulin sensitivity, may require dose adjustment [7]
- CYP450-metabolised drugs (e.g. cyclosporine, anticonvulsants, sex steroids): somatropin increases CYP450 clearance, potentially lowering levels of these medications [7]
- Octreotide / somatostatin analogues: antagonise GH effects and reduce IGF-1 response [14]
- Rotate injection sites with every administration to prevent lipodystrophy [7]
- Administer subcutaneously in the evening to mimic physiological nocturnal GH secretion [13]
- Start at the lowest effective dose and titrate up based on IGF-1 levels and tolerability — not body weight [13]
- Store refrigerated (2–8 °C); do not freeze; protect from light; discard after 28 days once opened [14]
- Never shake the reconstituted vial; swirl gently to dissolve [14]
Dosage context
Clinically prescribed adult GHD starting doses per Endocrine Society guidelines are 0.1–0.2 mg/day for older, obese, or diabetic patients and 0.4–0.5 mg/day for adults under 30 without diabetes, titrated upward in 0.1–0.2 mg/day increments every 1–2 months guided by IGF-1 levels [5][13]. These are medical prescription ranges, not general recommendations — dosing is highly individual and must be supervised by a physician.
Sources
- 1.FDA Prescribing Information – Accretropin (Somatropin)
- 2.Wikipedia – Growth hormone
- 3.NIH ClinicalInfo – Somatropin (Health Professional)
- 4.PeptideDosages.com – What is HGH 191AA?
- 5.NCBI Bookshelf – Somatropin for Growth Hormone Deficiency
- 6.PubMed PMC – Somatropin in GHD and Turner syndrome (review)
- 7.Drugs.com – Somatropin Uses, Dosage, Side Effects, Warnings
- 8.MedlinePlus – Somatropin Injection Drug Information
- 9.Mayo Clinic – Somatropin (E. coli derived), Subcutaneous Route
- 10.FDA Prescribing Information – Norditropin (Somatropin) Injection
- 11.RxList – Somatropin Side Effects, Uses, Dosage, Interactions
- 12.PubMed PMC – Mass spectrometric analysis of recombinant hGH (Genotropin)
- 13.Ageless Forever – Growth Hormone Therapy Dosing and Monitoring Guide
- 14.Healio – Somatropin: Uses, Side Effects & Dosage
This information is provided for educational and harm-reduction purposes only. It is not medical advice. These substances can carry serious health risks; effects and safe use vary by individual. Consult a qualified healthcare professional before use. Legal status varies by country — it is your responsibility to know your local law. We do not encourage misuse.
Other options for Somatropin - 191 Amino Acid· 24 offers
Same compound from different labs/brands and pack sizes. Tap a row to switch brand — the price and buy button update instantly.
This compound comes in different forms (e.g. injectable vs oral vs topical). Cost per mg is only comparable within the same form.
| Brand | Form | Strength | Pack | Price | Per mg |
|---|---|---|---|---|---|
Generic | vial | 2 mg | 1 vial | 54,90 € | — |
Generic | vial | 6 iu/vial | 10 vial | 139,99 € | — |
Generic | vial | 15 iu/vial | 10 vial | 144,90 € | — |
Generic | vial | 10 iu/vial | 10 vial | 144,90 € | — |
CinnaTropin | pen | 30 iu | 1 pen | 169,99 € | — |
Generic | vial | 100 iu/vial | 1 vial | 209,99 € | — |
Generic | vial | 12 iu/vial | 10 vial | 209,99 € | — |
Generic | vial | 10 iu/vial | 10 vial | 209,99 € | — |
Generic | — | — | 209,99 € | — | |
Generic | vial | 24 iu/vial | 10 vial | 249,99 € | — |
EVO | kit | — | 1 vial | 259,99 € | — |
DriadaSelected | kit | 10 iu/vial | 10 vial | 269,99 € | — |
Generic | kit | 100 iu | 100 iu | 319,99 € | — |
Pfizer | pen | 36 iu | 1 pen | 339,99 € | — |
Generic | kit | 10 iu/vial | 10 vial | 409,99 € | — |
Generic | — | — | 429,99 € | — | |
EVO | kit | — | 2 vial | 489,99 € | — |
Generic | vial | 10 iu/vial | 20 vial | 700,00 € | — |
Meta | kit | — | 5 vial | 1 100,00 € | — |
EVO | kit | — | 5 vial | 1 100,00 € | — |
CinnaTropin | kit | 30 iu | 10 pen | 1 100,00 € | — |
Generic | — | — | 1 300,00 € | — | |
Pfizer | pen | 36 iu | 5 pen | 1 400,00 € | — |
EVO | kit | — | 10 vial | 2 000,00 € | — |
Substance reviews(7)
Independent reviews of this compound from the wider market — about the substance, not our delivery. Showing the 6 with written feedback.
- ★★★★★16 days ago
Alles top wie immer Ware top Lieferung super Verpackung vllig unauffllig so wie es sein muss. Ich werde wieder bestellen ganz sicher!!
- ★★★★★2 months ago
Super!!!!
- ★★★★★7 months ago
+
Show all 6 reviews▾▴
- ★★★★★8 months ago
ultra fast shipping
- ★★★★★8 months ago
+++++++++
- ★★★★★12 months ago
Got original product within 3 days